American Optometric Association Meets with FTC to Discuss Proposed Contact Lens Rules, Advocate for Patient Safety

May 26, 2017

Media contact:
Deirdre Middleton, 703.837.1437

In addition to our comments to the Federal Trade Commission in January, AOA leaders and staff are continuing to urge agency officials to withdraw this harmful proposal that would impose new paperwork burdens on doctors and patients while not addressing the predatory practices of some online contact lens sellers which have the potential to harm patients and increase health care costs.

This meeting follows in-person meetings AOA conducted last week with key House and Senate leaders, including Sen. Bill Nelson (D-FL) and Reps. Bob Latta (R-OH) and Michael Burgess, M.D. (R-TX) on Capitol Hill to discuss the status of legislation to overhaul the health care system and to advocate for patient health and safety.

During the week of June 19, thousands of AOA doctors and students will have the chance to present the organization's priorities to U.S. Senators and House members as part of AOA on Capitol Hill, expected to be optometry's largest-ever advocacy event.

Related News

AOA Response to CNET EyeQue Review

With regard to your question--whether the EyeQue Vision Monitoring Kit is a good substitute for a trained professional, we can confidently say that, from a patient health and safety perspective, there is simply no replacement for an in-person comprehensive eye exam.

AOA Board of Trustees Statement Regarding C. Clayton Powell, O.D.

The Atlanta doctor of optometry and civil rights advocate fought to open doors for Black students interested in the profession, including helping to found the National Optometric Association.

American Optometric Association statement regarding CVS launch of QuickRenew

The AOA, affiliates and doctors of optometry call on CVS to acknowledge that this offering will lower the overall level of eye health care received by the public and that this test places them in the ranks of questionable vision tests apps that have and should continue to be investigated by the FDA.